Portola Pharmaceuticals

Therapeutics for acute and chronic cardiovascular, and autoimmune and inflammatory diseases.

Launch date

2003

Employees

Market cap

Enterprise valuation

€1.3b (Public information from May 2020)

San Francisco California (HQ)

Revenues, earnings & profits over time

EUR	2015	2016	2017	2018	2019
R&D budget	184m	234m	168m	188m	111m

Source: Dealroom estimates

Date	Investors	Amount	Round
-	Lightstone Ventures	N/A	-
Dec 2003	Abingworth Sutter Hill Ventures MPM BioImpact Prospect Venture Partners Frazier Healthcare Partners & 1 more	$21.0m	Series A
Nov 2005	Alta Partners Advanced Technology Ventures	$46.0m	Series B
May 2007	Goldman Sachs Abingworth Sutter Hill Ventures Ontario Teachers’ Pension Plan MPM BioImpact Alta Partners Brookside Capital AllianceBernstein Advanced Technology Ventures Frazier Healthcare Partners T. Rowe Price	$70.0m	Series C
Jul 2008	D.E. Shaw Group Sutter Hill Ventures MPM BioImpact Janus Capital Group Frazier Healthcare Partners Pac-Link IBT Management Corporation T. Rowe Price Prospect Venture Partners	$60.1m	Series C
Jun 2009	D.E. Shaw Group Adage Capital	$60.1m	Series C
Nov 2011	Temasek Eastern Capital	$89.0m	Series D
Dec 2011	N/A	$9.0m	Early VC
May 2013	N/A	N/A	IPO
Mar 2015*	N/A	$100m	Post IPO Equity
Dec 2015*	N/A	$150m	Post IPO Equity
Sep 2017*	N/A	$349m	Post IPO Equity
Mar 2019*	Athyrium Capital Management HealthCare Royalty	$125m	Post IPO Debt
Aug 2019*	N/A	$259m	Post IPO Equity
May 2020*	Alexion Pharmaceuticals	$1.4b Valuation: $1.4b	Acquisition
Total Funding		€323m

Tech stackLearn more about the technologies and tools that this company uses.

Financials